Cargando…
Neonatal Fc Receptor–Targeted Therapies in Neurology
Autoantibodies are increasingly recognized for their pathogenic potential in a growing number of neurological diseases. While myasthenia gravis represents the prototypic antibody (Ab)-mediated neurological disease, many more disorders characterized by Abs targeting neuronal or glial antigens have be...
Autores principales: | Nelke, Christopher, Spatola, Marianna, Schroeter, Christina B., Wiendl, Heinz, Lünemann, Jan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294083/ https://www.ncbi.nlm.nih.gov/pubmed/34997443 http://dx.doi.org/10.1007/s13311-021-01175-7 |
Ejemplares similares
-
Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis
por: Keller, Christian W., et al.
Publicado: (2021) -
Deregulated Fcγ receptor expression in patients with CIDP
por: Quast, Isaak, et al.
Publicado: (2015) -
Selection of Nanobodies that Target Human Neonatal Fc Receptor
por: Andersen, Jan Terje, et al.
Publicado: (2013) -
The Neonatal Fc Receptor (FcRn): A Misnomer?
por: Pyzik, Michal, et al.
Publicado: (2019) -
The therapeutic age of the neonatal Fc receptor
por: Pyzik, Michal, et al.
Publicado: (2023)